Cargando…

Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain

BACKGROUND: The purpose of this study was to investigate the savings accrued using bevacizumab-based treatment for non-small-cell lung cancer from the societal perspective, taking only public costs into account, in France, Germany, Italy, and Spain. METHODS: Societal costs were estimated by collecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lister, Johanna, Stanisic, Sanja, Kaier, Klaus, Hagist, Christian, Gultyaev, Dmitry, Walzer, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469277/ https://www.ncbi.nlm.nih.gov/pubmed/23071397 http://dx.doi.org/10.2147/CEOR.S34188

Ejemplares similares

Burden of vasomotor symptoms in France, Germany, Italy, Spain, and the United Kingdom
por: DiBonaventura, Marco daCosta, et al.
Publicado: (2013)

Modelling the initial epidemic trends of COVID-19 in Italy, Spain, Germany, and France
por: Wang, Kai, et al.
Publicado: (2020)

Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis
por: Xiao, Xian, et al.
Publicado: (2022)

Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
por: Chen, Clara, et al.
Publicado: (2015)

Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
por: YOKOI, TAKASHI, et al.
Publicado: (2014)

Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin(®)) in patients with advanced non-squamous non-small cell lung cancer
por: Li, Cheryl S. W., et al.
Publicado: (2019)

The Asylums of Italy, France, and Germany
por: Arlidge, J. T.
Publicado: (1859)

The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions
por: Campbell, David, et al.
Publicado: (2018)

Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression
por: Cardona, Andrés Felipe, et al.
Publicado: (2016)

Data on Income inequality in Germany, France, Italy, Spain, the UK, and other affluent nations, 2012
por: Dorling, Danny
Publicado: (2015)

Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience
por: Marín-Pozo, Juan F., et al.
Publicado: (2016)

The Asylums of Italy, Germany, and France, &c.
por: Arlidge, J. T.
Publicado: (1858)

Notes on the Asylums of Italy, France, and Germany
por: Arlidge, J. T.
Publicado: (1860)

Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer
por: Reck, Martin, et al.
Publicado: (2020)

Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)
por: Syrigos, Konstantinos, et al.
Publicado: (2021)

Non-arteritic ischemic optic neuropathy followed by intravitreal bevacizumab injection: Is there an association?
por: Bodla, Ali A, et al.
Publicado: (2010)

Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab
por: Stinchcombe, Thomas E
Publicado: (2007)

Intravitreal Bevacizumab for Choroidal Neovascularization Secondary to Non-Age-Related Macular Degeneration
por: Salehipour, Masoud, et al.
Publicado: (2010)

Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)
por: Chien, Chun-Ru, et al.
Publicado: (2012)

Intracameral bevacizumab administered for non-small cell lung cancer metastasis to iris
por: Schell, Jonathan C., et al.
Publicado: (2011)

Intravitreal bevacizumab versus ranibizumab: Effects on the vessels of the fellow non-treated eye
por: Peyman, Mohammadreza, et al.
Publicado: (2018)

The Risk of Non-arteritic Ischemic Optic Neuropathy Post-intravitreal Bevacizumab Injection
por: Fugara, Nasser A, et al.
Publicado: (2022)

Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L)
por: Takeda, Masayuki, et al.
Publicado: (2012)

The Incidence, Prevalence, and Mortality of Stroke in France, Germany, Italy, Spain, the UK, and the US: A Literature Review
por: Zhang, Younan, et al.
Publicado: (2012)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Intravitreal bevacizumab
por: Khamar, Bakulesh M
Publicado: (2018)

Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study
por: Zhao, Zhiting, et al.
Publicado: (2023)

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
por: Hummel, Matthew, et al.
Publicado: (2021)

Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain
por: Calleja, Miguel Angel, et al.
Publicado: (2023)

Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
por: Zhang, Shu, et al.
Publicado: (2016)

COVID-19 and Territorial Policy Dynamics in Western Europe: Comparing France, Spain, Italy, Germany, and the United Kingdom
por: Vampa, Davide
Publicado: (2021)

EU Member States’ Institutional Twitter Campaigns on COVID-19 Vaccination: Analyses of Germany, Spain, France and Italy
por: Tuñón Navarro, Jorge, et al.
Publicado: (2023)

FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer
por: Bertolini, F, et al.
Publicado: (2011)

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
por: Boutsikou, Eftimia, et al.
Publicado: (2013)

Bevacizumab treatment for advanced non-small cell lung cancer: A case report
por: FAN, YUN, et al.
Publicado: (2013)

Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients
por: Martino, EC, et al.
Publicado: (2016)

Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
por: Wan, Guoxing, et al.
Publicado: (2019)

Re-188 Enhances the Inhibitory Effect of Bevacizumab in Non-Small-Cell Lung Cancer
por: Xiao, Jie, et al.
Publicado: (2016)

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
por: Schneider, Benjamin K., et al.
Publicado: (2019)

Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases
por: Ascha, Mustafa S., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fk0eae62g2n2nu9ppc5r0ltf73